close

Antigenics Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases, primarily based on immunological approaches. Its products include Oncophage (vitespen), a patient-specific therapeutic cancer vaccine registered for use in the Russia Federation, as well as under review by the European Medicines Agency for the treatment of kidney cancer patients with earlier-stage disease. The company tested Oncophage in phase 3 clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and phase 1 and phase 2 clinical trials for various indications, as well as in phase 2 clinical trial for the treatment of recurrent glioma, a type of brain cancer. Its product candidate portfolio also includes QS-21 Stimulon adjuvant, which is used in various vaccines under development in trials for diseases, such as hepatitis, human immunodeficiency virus, influenza, cancer, Alzheimer's disease, malaria, and tuberculosis; AG-707, a therapeutic vaccine program for the treatment of genital herpes; and Aroplatin, a liposomal chemotherapeutic for the treatment of solid malignancies and B-cell lymphomas. The company was formerly known as Antigenics L.L.C. and changed its name to Antigenics, Inc. in February 2000. Antigenics was founded in 1994 and is headquartered in Lexington, Massachusetts.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	5.45
Volume	573039
Volume Avg	148423
52 Week High	6.72
52 Week Low	1.92
PE	N/A
PE (group average)	39
EPS Year	-1.21
EPS change Q/Q	-66.67%
EPS change Q/Q Yr ago	-50%
EPS change Q/Q next Q est	-82.14%
EPS change Y/Y	-100%
REV change Q/Q	-30%
REV change Q/Q Yr ago	-22.22%
EPS next Q est	-0.28
EPS next Y est	-1.30
Divident Annual	0.00
Dividend Yield	0%